APR 13, 2017 10:30 AM PDT

Why Variants Matter: NGS Bioinformatics Simplified for Oncology & Virology

SPONSORED BY: Vela Diagnostics
2 1 132

  • Vice President of Precision Oncology, Vela Dx
      Condie Carmack, Ph.D. received his Ph.D. from the University of Utah in Experimental Pathology and did postdocs in Philadelphia, PA and San Diego, CA. in mouse genetics and molecular biology. He is the author or or co-author of 23 peer-reviewed journal. He wrote the first paper on quantitative PCR and the second paper on multiplex PCR. He served on the Science Advisory Board of Life Technologies Inc. as an expert in clinical PCR. He was co-author on the first paper creating human monoclonal antibodies from immunodeficient mice. Mice serve as the foundation for creation of the current immune checkpoint blockade antibodies such as ipilimumab and nivolumab. He also served as General Manager of the Cancer Genetics Lab at Baylor College of Medicine before joining Vela Diagnostics
    • Director of Scientific Support for Vela Diagnostics, Bioinformatics Applications scientist
        Ahmed Mahmoud is an experienced scientist with both hands-on lab and bioinformatics experience with degrees in both molecular biology and bioinformatics. Ahmed is currently the Director of Scientific Support for Vela Diagnostics as well as a Bioinformatics Applications scientist. Ahmed's team handles all technical wet lab and informatics support for Vela Diagnostic's qPCR and NGS workflows, assisting with pipeline creation for various NGS workflows and robotic application writing for automated systems. He has experience developing qPCR and Automated NGS workflows as well as extensive experience in NGS data analysis using multiple sequencing platforms. He has held positions in various areas of the biotech industry with institutions such as GeneDX, Pfizer and Columbia University Medical Center. Ahmed is also an avid iOS developer, creating computer apps geared towards the science sector.


      Next-generation sequencing is expected to take molecular diagnostics to the next level with the capability to perform deep analysis of genetic information that leads to targeted therapies perfectly matched to the situation. However, adoption of this technology in the clinic has been slower than expected due to various factors including ease-of-use, expense, footprint, and data complexity.  Today many of these hurdles have been overcome as NGS workflows have become increasingly automated, smaller, and less expensive.  For many in the clinic, the key to making this technology more accessible is automated bioinformatics that supports clinical decision-making.

      In this presentation we will delve into the sequencing world from the perspective of the variant.  We’ll uncover how today’s sophisticated bioinformatics engines can take raw sequencing data and transform the results into accurate and actionable reports that point to therapies and clinical trials.  We will explore this concept for clinical oncology and clinical virology and show how software today automates the process from sample-to -answer.

      Show Resources
      Loading Comments...